Yehu Ofer, Chief Executive Officer of Odysight.ai commented:“2025 was a transformative year for Odysight.ai. We successfully transitioned from our legacy medical business and are now fully focused on ...
L1, EBV and mismatch repair deficiency suggests CLDN18.2 stratification must be integrated into multi-biomarker algorithms rather than used in isolation. Treatment interactions emerged: CLDN18.2-high ...
TV ratings for the ceremony itself were unusually low, but interest in the fashion — as measured by social media engagement — has never been higher.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results